Targeting Suppressor of Variegation 3-9 Homologue 2 (SUV39H2) in Acute Lymphoblastic Leukemia (ALL)()

Although recent progress in understanding the biology and optimizing the treatment of acute lymphoblastic leukemia (ALL) has improved cure rates of childhood ALL to nearly 90%, the cure rate in adult ALL remains less than 50%. The poor prognosis in adult ALL has in part been attributed to larger pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Mutonga, Martin, Tamura, Kenji, Malnassy, Gregory, Fulton, Noreen, de Albuquerque, Amanda, Hamamoto, Ryuji, Stock, Wendy, Nakamura, Yusuke, Alachkar, Houda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4631083/
https://www.ncbi.nlm.nih.gov/pubmed/26500027
http://dx.doi.org/10.1016/j.tranon.2015.07.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4631083/
https://www.ncbi.nlm.nih.gov/pubmed/26500027
http://dx.doi.org/10.1016/j.tranon.2015.07.003

Ejemplares similares